The weight I lost with GLP-1s came back ‘with taxes’

Stopping GLP-1 medications often triggers a rapid rebound in body weight, overturning the expectation that lost pounds stay gone. Readers report that the kilograms shed on drugs like Ozempic surge back almost as quickly after the last dose, a pattern described as a ‘weight regain curve.’ The surprise lies in the speed and magnitude of the bounce‑back, contradicting the promise of lasting loss. TechBuzzIreland outlines the post‑therapy trajectory, while Bioengineer.org cites a major analysis confirming fast regain after semaglutide or tirzepatide cessation.

Drug Topics adds that a predictive model quantifies the rebound, reinforcing the clinical expectation. Medscape contributes a practical angle, advising clinicians on strategies to manage depression that can accompany the weight return. Together the pieces illustrate a consensus across biotech, medical and tech‑focused publications that the effect is both swift and widespread.

The rebound complicates long‑term weight‑management plans, signaling that discontinuation may require ongoing monitoring and support. The reports do not prescribe a universal solution, but they flag mental‑health implications and the need for integrated care. Readers are left with the understanding that while GLP-1 drugs deliver rapid loss, sustaining that benefit after stopping remains uncertain and may involve additional therapeutic or behavioural interventions.